Abstract Background: Recent studies suggest that sustained use of generic antibiotics may be associated with clinical failure and emergence of antibacterial resistance. The present study was designed to determine the clinical outcome between the use of generic meropenem (GM) and brand-name meropenem (BNM). Additionally, this study evaluated the economic impact of GM and BNM to determine if the former represents a cost-effective alternative to the latter. Methods: Patients treated between January 2011 and May 2014 received GM while patients treated between June 2014 and March 2017 received BNM. Mortality was compared between groups. Total infection cost was defined by the cost of antimicrobial consumption, length of stay, and laboratory and imaging exams until infection resolution. Findings: A total of 168 patients were included; survival rate for the 68 patients treated with GM was 38% compared to 59% in the patients treated with BNM. Multivariate analysis showed that the variables most strongly-associated with mortality were cardiovascular disease (OR 18.18, 95% CI 1.25-262.3, p = 0.033) and treatment with generic meropenem (OR 18.45, 95% CI 1.45-232.32, p = 0.024). On the other hand, total infection cost did not show a significant difference between groups (BNM $10,771 vs. GM $11,343; p = 0.91). Interpretation: The present study suggests that patients treated with GM have a risk of death 18 times higher compared to those treated with BNM. Furthermore, economic analysis shows that GM is not more cost effective than BNM. Summary: More studies measuring clinical outcomes are needed to confirm the clinical equivalence of brand-name versus generic antibiotics, not only for meropenem but also for other molecules.

Resumen Introducción. La microcefalia consiste en una circunferencia cefálica menor de la esperada. Recientemente, el virus del Zika se ha asociado con esta condición. Objetivo. Describir la prevalencia de la microcefalia en Colombia, estableciendo como línea de base el periodo anterior a la epidemia del virus del Zika. Materiales y métodos. Se revisaron las bases de datos Medline, Scopus, Scielo, Lilacs y el reporte anual de malformaciones congénitas en Latinoamérica, así como otras fuentes publicadas antes de abril de 2015 con los datos de prevalencia de la microcefalia en Colombia entre 1982 y 2013. Resultados. Se detectaron 32 artículos no duplicados, se revisaron 25 y se seleccionaron 12 que cumplían con los criterios de inclusión para la revisión sistemática, los cuales registraban 2’808.308 nacimientos. Conclusiones. La prevalencia de la microcefalia en Colombia entre 1982 y 2013, antes de la epidemia del virus del Zika, oscilaba entre 0,3 y 3,1 por 10.000 nacimientos, con un promedio de 1,8 (IC95% 1,7-1,8). Este dato es importante para determinar la diferencia en la prevalencia después de la introducción del virus del Zika en Colombia.

Abstract Introduction: Microcephaly is characterized by a smaller than normal head circumference. Recently, Zika virus (ZV) has been associated with microcephaly. Objective: To describe the prevalence of microcephaly in Colombia taking as the baseline the information from the period before the Zika virus infection epidemics. Materials and methods: We reviewed Medline, Scopus, Scielo, Lilacs and annual reports of congenital malformation monitoring systems across Latin America, among others sources, for articles published before April, 2015, reporting the prevalence of microcephaly in Colombia between 1982 and 2013. Results: We identified 32 non-duplicate articles; we selected 25 articles for revision of which 12 met the criteria for inclusion in the systematic review, including 2,808,308 births. Conclusions: The prevalence of microcephaly in Colombia from 1982 to 2013, before the introduction of ZV, ranged from 0.3 to 3.1 per 10,000 births, with an average of 1.8 (95% CI 1.7-1.8) per 10,000 births. These findings are important to determine if the prevalence after the introduction of the Zika virus infection registered significant changes.